JP2025011142A5 - - Google Patents

Info

Publication number
JP2025011142A5
JP2025011142A5 JP2024168470A JP2024168470A JP2025011142A5 JP 2025011142 A5 JP2025011142 A5 JP 2025011142A5 JP 2024168470 A JP2024168470 A JP 2024168470A JP 2024168470 A JP2024168470 A JP 2024168470A JP 2025011142 A5 JP2025011142 A5 JP 2025011142A5
Authority
JP
Japan
Prior art keywords
application
invention described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024168470A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025011142A (ja
JP7886110B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2019/064032 external-priority patent/WO2020113224A2/en
Application filed filed Critical
Publication of JP2025011142A publication Critical patent/JP2025011142A/ja
Publication of JP2025011142A5 publication Critical patent/JP2025011142A5/ja
Application granted granted Critical
Publication of JP7886110B2 publication Critical patent/JP7886110B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024168470A 2018-11-30 2024-09-27 キメラ抗原受容体ファクトリおよびその使用方法 Active JP7886110B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862773885P 2018-11-30 2018-11-30
US62/773,885 2018-11-30
US201962826462P 2019-03-29 2019-03-29
US62/826,462 2019-03-29
PCT/US2019/064032 WO2020113224A2 (en) 2018-11-30 2019-12-02 Chimeric antigen receptor factories and methods of use thereof
JP2021530875A JP7649239B2 (ja) 2018-11-30 2019-12-02 キメラ抗原受容体ファクトリおよびその使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021530875A Division JP7649239B2 (ja) 2018-11-30 2019-12-02 キメラ抗原受容体ファクトリおよびその使用方法

Publications (3)

Publication Number Publication Date
JP2025011142A JP2025011142A (ja) 2025-01-23
JP2025011142A5 true JP2025011142A5 (cg-RX-API-DMAC7.html) 2025-10-15
JP7886110B2 JP7886110B2 (ja) 2026-07-07

Family

ID=70853578

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021530875A Active JP7649239B2 (ja) 2018-11-30 2019-12-02 キメラ抗原受容体ファクトリおよびその使用方法
JP2024168470A Active JP7886110B2 (ja) 2018-11-30 2024-09-27 キメラ抗原受容体ファクトリおよびその使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021530875A Active JP7649239B2 (ja) 2018-11-30 2019-12-02 キメラ抗原受容体ファクトリおよびその使用方法

Country Status (6)

Country Link
US (1) US12577311B2 (cg-RX-API-DMAC7.html)
EP (1) EP3887509A4 (cg-RX-API-DMAC7.html)
JP (2) JP7649239B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210135475A (cg-RX-API-DMAC7.html)
CA (1) CA3119644A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020113224A2 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3526257A2 (en) * 2016-10-14 2019-08-21 Dana-Farber Cancer Institute, Inc. Modular tetravalent bispecific antibody platform
CN109401969B (zh) * 2018-12-13 2024-02-02 珠海西格膜生物技术有限公司 一种细胞工厂的管道连接系统及其使用方法
JP7680967B2 (ja) * 2019-06-14 2025-05-21 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド Pd-1に対する抗体およびその使用方法
AU2020291946B2 (en) * 2019-06-14 2026-08-06 Dana-Farber Cancer Institute, Inc. Antibodies against PD-1 and methods of use thereof
EP4226972A4 (en) * 2020-10-12 2025-01-01 Nanjing Iaso Biotechnology Co., Ltd. CD70-BINDING ANTIBODY AND CHIMERIC ANTIGEN RECEPTORS (CAR) AND THEIR USE
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
IL303269A (en) 2020-12-03 2023-07-01 Century Therapeutics Inc Genetically engineered cells and uses thereof
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
EP4355358A1 (en) * 2021-06-15 2024-04-24 Allogene Therapeutics, Inc. Selective targeting of host cd70+ alloreactive cells to prolong allogeneic car t cell persistence
CN114565761B (zh) * 2022-02-25 2023-01-17 无锡市第二人民医院 一种基于深度学习的肾透明细胞癌病理图像肿瘤区域的分割方法
EP4536296A1 (en) * 2022-06-09 2025-04-16 Telix Pharmaceuticals (Innovations) Pty Ltd Combination therapy
TW202442689A (zh) * 2023-03-03 2024-11-01 美商亞森諾生物科學公司 靶向psma及ca9之系統
WO2026117664A1 (en) * 2024-11-26 2026-06-04 Dana-Farber Cancer Institute, Inc. Engineered cells and uses thereof for treating cancer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US8329178B2 (en) 2005-02-18 2012-12-11 Dana-Farber Cancer Institute, Inc. Antibodies against CXCR4 and methods of use thereof
EP1979379B1 (en) 2005-12-02 2013-09-18 Dana-Farber Cancer Institute Carbonic anhydrase ix (g250) antibodies and methods of use thereof
WO2009086514A1 (en) 2007-12-28 2009-07-09 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
WO2011139375A1 (en) * 2010-05-06 2011-11-10 Ludwig Institute For Cancer Research Ltd Antibodies directed against carbonic anhydrase ix and methods and uses thereof
BR112013021562B1 (pt) * 2011-03-16 2023-01-10 Argenx Bvba Anticorpos para cd70
EP2814846B1 (en) * 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
AU2013256010B2 (en) 2012-05-04 2018-01-04 Dana-Farber Cancer Institute, Inc. Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use
CA2962949C (en) 2014-10-06 2024-03-05 Dana-Farber Cancer Institute, Inc. Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof
US20180334490A1 (en) * 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
WO2016100980A1 (en) 2014-12-19 2016-06-23 Dana-Farber Cancer Institute, Inc. Carbonic anhydrase ix specific chimeric antigen receptors and methods of use thereof
RU2017125531A (ru) 2014-12-19 2019-01-21 Дана-Фарбер Кэнсер Инститьют, Инк. Химерные антигенные рецепторы и способы их применения
WO2016149578A1 (en) 2015-03-19 2016-09-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dual specific anti-cd22-anti-cd19 chimeric antigen receptors
US20190031759A1 (en) * 2015-04-30 2019-01-31 Technion Research & Development Foundation Limited Chimeric antigen receptors and methods of their use
EP3288977B1 (en) 2015-05-01 2021-11-17 Dana-Farber Cancer Institute, Inc. Methods of mediating cytokine expression with anti ccr4 antibodies
WO2017075537A1 (en) * 2015-10-30 2017-05-04 Aleta Biotherapeutics Inc. Compositions and methods for treatment of cancer
EP3583129B1 (en) * 2017-02-14 2021-11-03 Kite Pharma, Inc. Cd70 binding molecules and methods of use thereof
EP3585817A4 (en) * 2017-02-22 2020-12-02 Aleta Biotherapeutics Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
WO2019178356A1 (en) 2018-03-14 2019-09-19 Dana-Farber Cancer Institute, Inc. Engineered cells, t cell immune modulating antibodies and methods for using the same

Similar Documents

Publication Publication Date Title
JP2025027013A5 (cg-RX-API-DMAC7.html)
JP2024116190A5 (cg-RX-API-DMAC7.html)
JP2023115329A5 (cg-RX-API-DMAC7.html)
JP2024036694A5 (cg-RX-API-DMAC7.html)
JP2024032941A5 (cg-RX-API-DMAC7.html)
JP2025176106A5 (cg-RX-API-DMAC7.html)
JP2023171775A5 (cg-RX-API-DMAC7.html)
JP2022184985A5 (cg-RX-API-DMAC7.html)
JP2023166402A5 (cg-RX-API-DMAC7.html)
JP2023103258A5 (cg-RX-API-DMAC7.html)
JP2024114921A5 (cg-RX-API-DMAC7.html)
JP2023145572A5 (cg-RX-API-DMAC7.html)
JP2024161376A5 (cg-RX-API-DMAC7.html)
JP2025069142A5 (cg-RX-API-DMAC7.html)
JP2024150466A5 (cg-RX-API-DMAC7.html)
JP2023181322A5 (cg-RX-API-DMAC7.html)
JP2022024034A5 (cg-RX-API-DMAC7.html)
JP2025098156A5 (cg-RX-API-DMAC7.html)
JP2023502517A5 (cg-RX-API-DMAC7.html)
JP2024149687A5 (cg-RX-API-DMAC7.html)
JP2024099585A5 (cg-RX-API-DMAC7.html)
JP2024045126A5 (cg-RX-API-DMAC7.html)
JP2025094038A5 (cg-RX-API-DMAC7.html)
JP2025090801A5 (cg-RX-API-DMAC7.html)
JP2023093656A5 (cg-RX-API-DMAC7.html)